C-terminal lysine conjugated immunoglobulins

A technology of immunoglobulin and terminal lysine, applied in the field of C-terminal lysine conjugated immunoglobulin, which can solve the problem of low specificity of acyl acceptor amine

Active Publication Date: 2018-09-28
EISIA R&D MANAGEMENT CO LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Due to the low specificity of microbial transglutaminases for acyl acceptor amines, studies to date have only focused on the transamidation of antibody glutamine residues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • C-terminal lysine conjugated immunoglobulins
  • C-terminal lysine conjugated immunoglobulins
  • C-terminal lysine conjugated immunoglobulins

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0216] Example 1: Materials and methods

[0217] mutagenesis

[0218] Mutations were generated using Stratagene's QuikChange XL according to the manufacturer's protocol. Desired mutations were confirmed by DNA sequencing.

[0219] Transfection and stable cell line generation

[0220] For each ml of cells to be transfected with ExpiFectamine, 333.3 ng of HC plasmid and 333.3 ng of LC plasmid were incubated in 50 μL of Opti-MEM (ThermoFisher) for 5-10 min. Similarly, 2.67 μL of ExpiFectamine was incubated in 50 μL of Opti-MEM. Add the ExpiFectamine solution to the DNA mixture and incubate at room temperature for 20-30 minutes. Add the DNA:ExpiFectamine mixture to the cells while rotating and incubating at 37 °C, 8% CO 2 Incubate with shaking at 125rpm. The next day, 5 µL of Enhancer 1 and 50 µL of Enhancer 2 per mL of cells were added to the transfection and the incubation continued for another 7-10 days.

[0221] 1 to 3 days after transfection, select for antibody-ex...

Embodiment 2

[0247] Example 2: Analysis of solvent exposed lysine on IgG antibodies

[0248] IgG was detected 1 -κFab (antibody 01,4F3F), IgG 1 -λFab(4HK0) and IgG 1 Crystal structure of Fc(1FC1) for potential acyl acceptor sites. Since microbial transglutaminases tend to prefer the solvent-exposed substrate glutamine and intracyclic lysine {Spolaore, 2012 17 / id}, solvents were highlighted using Discovery Studio v4.5 with a 1.4 angstrom probe radius Exposed lysine (Figure 4). In Antibody 01 VH there are 7 solvent exposed lysines and 3 are in the loop. Since the number of lysines can vary between mAbs utilizing different variable region families and somatic hypervariation, lysines in the VH regions of five other antibodies were also analyzed based on the similar positions of the residues in the 4F3F structure of solvent exposure. These VH regions may contain 1-5 solvent-exposed lysines, 1 or 2 present in loops. In antibody 01 VK there are 6 solvent exposed lysines and 4 are in the lo...

Embodiment 3

[0263] Example 3: A single amino acid extension is sufficient for transamidation of Lys447

[0264] Lys447 is normally cleaved by carboxypeptidase B during recombinant IgG expression in HEK293 and CHO cells {Harris, 1990 7 / id; Harris, 1995 6 / id; Dick, 2008 3 / id}. However, addition of KTag to the HC C-terminus blocks the removal of Lys447, thereby allowing microbial transglutaminases to utilize Lys447 as an acyl acceptor site. To determine whether microbial transglutaminases could use Lys447 as a KTag-free acyl acceptor, Lys447 was cleaved by adding one or two leucines to the C-terminus of Antibody 01 (Antibody 01-HC-L or Antibody 01-HC-L or Antibody 01-HC-LL) to block. Purified mAbs were incubated with Z-Gln-Gly-CAD-biotin and microbial transglutaminase and analyzed for the mass of deglycosylated HC. Indeed, addition of one or two leucines preserved Lys447 and modified the HC with a single acyl donor substrate consistent with transamidation of Lys447 (Figure 8; Table 3).

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.

Description

[0001] related application [0002] This application claims priority to US Provisional Application No. 62 / 269,138, filed December 18, 2015, the entire contents of which are expressly incorporated herein by reference. technical field [0003] Provided herein are C-terminal lysine conjugated immunoglobulins and methods for their preparation. Background technique [0004] The utility of monoclonal antibodies extends from basic research to therapeutic and diagnostic applications. The ability to conjugate antibodies to functional agents extends their functionality even further. The manufacture of conjugated antibodies typically involves the conjugation of linkers, drugs, or other functional agents to reactive lysine cysteine ​​residues on the heavy (HC) and light (LC) chains of monoclonal antibodies (mAbs). See Deonarain, et al., "Emerging formats for next-generation antibody drug conjugates", Expert Opinion in Drug Discovery (2015), 10(5):463-481. Lysine conjugation is usual...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/00
CPCC07K16/00A61K47/68A61K47/6811A61K47/6863A61P35/00A61K51/1096C12P21/00A61K47/6851A61P31/00C12Y203/02013A61K47/6875C07K2317/14A61K47/6883C07K2317/24A61K47/6887C07K2317/31A61K49/16C07K2317/526A61K47/6889C07K2317/40A61K47/6801A61K51/1093C12N9/1044A61K47/60A61K51/1087C07K2317/528A61K51/109C07K2317/55A61K49/0058C07K2317/522
Inventor J·斯皮德尔E·阿尔邦
Owner EISIA R&D MANAGEMENT CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap